Independent Advisor Alliance Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Independent Advisor Alliance purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 19,187 shares of the medical equipment provider's stock, valued at approximately $2,027,000.

A number of other hedge funds have also added to or reduced their stakes in ZBH. Roman Butler Fullerton & Co. acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $473,000. Geode Capital Management LLC lifted its stake in Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after purchasing an additional 125,852 shares during the last quarter. M&T Bank Corp boosted its position in Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after buying an additional 8,709 shares in the last quarter. KLCM Advisors Inc. bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $654,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 1.7 %

Shares of ZBH traded up $1.88 during trading hours on Monday, hitting $111.85. The stock had a trading volume of 2,435,739 shares, compared to its average volume of 1,484,314. The firm has a 50 day simple moving average of $105.83 and a 200-day simple moving average of $106.92. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market capitalization of $22.26 billion, a P/E ratio of 25.13, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm posted $2.20 earnings per share. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.95% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research reports. Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Stifel Nicolaus increased their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Raymond James cut their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.